eli lilly and company zepbound

Eli Lilly’s stock falls

Eli Lilly CEO expects new weight loss pill to be approved next year

Eli Lilly and its rivals are working to develop more convenient options than the injectable Zepbound and Wegovy, which dominate the weight loss drug market.

MarketWatch · 1d

Eli Lilly’s stock falls as weight-loss drug sales disappoint

Shares of Eli Lilly and Co. slipped 0.4% in premarket trading Tuesday, after the drug maker provided a disappointing fourth-quarter revenue outlook, citing slower-than-expected growth in sales of its weight-loss drugs.

invezz on MSN · 2h

Eli Lilly cuts Q4 sales forecast, but analyst remains bullish on stock—here’s why

Eli Lilly (LLY) reduced its fourth-quarter sales guidance by 5%, lowering expectations to $13.5 billion. This figure is $400 million below the low end of the company’s prior guidance and includes $3.5 billion from its type 2 diabetes drug Mounjaro and $1.

STAT1h

Eli Lilly is considering offering more Zepbound doses in vials at lower cost

Lilly’s decision to offer vials has also been seen as its way to combat the rise in compounding. Patients have been turning ...

Eli Lilly: Big 2025 Ahead, But Execution Risks Exist

Eli Lilly's stock dipped due to cutting Q4 sales targets, despite a strong 2024 performance from Mounjaro and Zepbound. Click ...

9hon MSN

These Stocks Are Moving the Most Today: JPMorgan, Wells Fargo, BlackRock, Eli Lilly, D-Wave Quantum, and More

Shares of Wells Fargo rose 3.9% after the San Francisco bank’s fourth-quarter profit of $1.43 a share beat expectations of $1 ...

STAT3h

Eli Lilly CEO on Trump, obesity drugs, and a guidance miss

In a live taping of "The Readout LOUD" at #JPM25, Eli Lilly CEO Dave Ricks talks Trump, Medicare's drug price negotiation, ...

Why Eli Lilly, Novo Nordisk, and Viking Therapeutics Stocks All Dropped on Tuesday

Turning to 2025 guidance, Lilly noted that new medicines and new uses of existing medicines, expansion of production, and ...

19hon MSN

Watch These Eli Lilly Price Levels as Stock Slumps on Tepid Sales Outlook

Eli Lilly shares could remain under the microscope on Wednesday after falling sharply Tuesday as the pharmaceutical giant ...

Eli Lilly Adjusts Outlook, CEO David Ricks Explains Revenue Shortfall

Eli Lilly forecasts $45 billion revenue for 2024, 32% higher than last year. Medicare changes and stocking issues impact the revised guidance.

BioSpace1d

Lilly Projects 2024 Revenue Miss as Zepbound, Mounjaro Disappoint

The updated guidance, which was largely driven by lower-than-anticipated sales of GLP-1 blockbusters Mounjaro and Zepbound, ...

FiercePharma23h

JPM25: Eli Lilly's preliminary '24 sales figures show a continued easing in breakneck GLP-1 market

Unfortunately for the company, however, the early glimpse at its fourth-quarter performance doesn’t seem to be going over ...

Yahoo Finance1d

Eli Lilly and Company (LLY)

Eli Lilly and Company (NYSE: LLY) today announced the U.S. Food and Drug Administration (FDA) approved Zepbound® (tirzepatide) as the first and only prescription medicine for adults with ...

22h

Eli Lilly and Company (LLY) CEO Dave Ricks presents at 43rd Annual J.P. Morgan Healthcare Conference (Transcript)

Eli Lilly and Company (NYSE:LLY) 43rd Annual J.P. Morgan Healthcare Conference January 14, 2025 5:15 PM ETCompany ParticipantsDave Ricks - Chairman ...

1don MSN

Eli Lilly’s Zepbound and Mounjaro Sales Missed Estimates Again. The Wobble’s Looking Serious.

The results are an uncomfortable echo of late October 2024, when Mounjaro and Zepbound missed by similar margins. Those ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results